These 3 ASX biotech shares are all up at least 120% in a year

Shares in ASX biotech companies Anteotech Ltd (ASX: ADO), Imugene Ltd (ASX: IMU) and Little Green Pharma Ltd (ASX: LGP) have all posted exciting gains over the past 12 months.

Let’s have a look at the share price performance and recent news of all 3 ASX shares.

Little Green Pharma

At the time of writing, shares in this cannabis manufacturing and distribution company have climbed 121.1% over the course of 1 year. Little Green Pharma shares are also 15.33% up on the previous 5 days and 17.91% on the previous month.

Over the year-to-date, the company’s shares have posted a return of 41%, having come off a high of 94 cents on 4 February 2021.

Over the previous 6 months, the company has reported 2 major announcements, including a firm purchase order from Denmark company Demecan for 9,000 units of flower, and signing an exclusive distribution deal with leading Polish pharmaceutical group Pelion SA.

With a share price of 79.5 cents at the time of writing, Little Green Pharma has a market capitalisation of $104.6 million, and currently has negative earnings per share.

Anteotech

The Anteotech share price has climbed 159% this year-to-date, however is 1.72% down at the time of writing.

Over the previous 5 days, Anteotech shares have gained 26.67%, giving the company a market capitalisation of around $556 million. Shares are trading off their 52-week high of 49.5 cents, but are above the 52-week low of 2 cents.

Over the year-to-date, the company has procured a specified manufacturing line in Brisbane as apart of its EuGeni Test Strip Manufacturing Strategy, forming part of a “decentralised and diversified global manufacturing approach”.

According to a press release on 24 May 2021, the company expects an additional capacity of 12 million strips per annum as a result of the initiative.

Imugene

The Imugene share price has surged by 277% year-to-date, recently down from a high of 49 cents, coming in today at 38 cents at the time of writing.

The company is up 4.05% intraday, and has gained 10% over the previous 5 days. Imugene’s market capitalisation has now reached $1.8 billion, but it has experienced a 1-month drop of 17% from the previous month.

Over the previous 6 months, the company has presented a series of positive data on clinical trial outcomes. Back in April 2021, the company released positive headline results for its phase 2 gastric cancer clinical trial.

Furthermore, on 18 May 2021, the company also announced the commencement of a phase 1 clinical trial in 2022 to expand on Imugene’s expertise in oncolytic virus and cell therapy technology, for investigation in therapy for solid tumours.

Foolish takeaway

These 3 ASX biotech shares have each outperformed the broader Australian index this year, posting returns above the S&P/ASX 200 Index (ASX: XJO)’s 11% year-to-date.

The post These 3 ASX biotech shares are all up at least 120% in a year appeared first on The Motley Fool Australia.

More reading

• Why the Little Green Pharma (ASX:LGP) share price fired up 8% today
• NAB and Zip were among the most traded ASX shares last week
• Here’s why the Little Green Pharma (ASX:LGP) share price is down 5%
• The Imugene (ASX:IMU) share price has fallen 14% in the last 5 days
• These 3 ASX 200 shares are the most actively traded today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3xZ8yM6